Skip to main
  1. Stocks
  2. Allarity Therapeutics
  3. Forecast
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is viewed favorably because its DRP platform may improve patient selection and increase the probability that stenoparib shows meaningful benefit in advanced ovarian cancer and recurrent SCLC, supporting a precision-medicine edge in a high-unmet-need setting. Clinical signals are encouraging, with multiple ovarian cancer patients exceeding 30 weeks on therapy, two still benefiting more than 29 months as of March 2026, and median overall survival now exceeding 25 months, while SCLC first dosing in February 2026 broadens the pipeline. Financially, the company had $20 million in cash and $22 million in debt in Q1, and exposure to a PARP inhibitor market that generated about $9.0 billion in 2023 and is forecast to surpass $21.0 billion by 2031 adds substantial commercial upside.

Bears say

Allarity Therapeutics is a clinical-stage company with essentially no revenue, reporting about $0 million in both Q1 2026 and Q2 2026, while posting net losses of $2.8 million and $3.4 million, respectively, underscoring its dependence on external funding rather than operating cash flow. Its lead stenoparib program still faces long development challenges, and the company’s value remains highly contingent on clinical success, regulatory approval, and eventual commercialization of a precision-medicine strategy that has yet to prove itself. The negative outlook is further supported by explicit balance sheet and liquidity risks, plus the possibility that safety, efficacy, reimbursement, competition, and broader biotech sentiment could all delay or impair progress.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction

Get the latest Allarity Therapeutics (ALLR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Allarity Therapeutics (ALLR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Oct 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction

Get the latest Allarity Therapeutics (ALLR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Allarity Therapeutics (ALLR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ALLR stock data and trends